Date: 2014-07-24
Type of information: Nomination
Compound: chairman of the board of directors
Company: Protalix BioTherapeutics (Israel)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 24, 2014, Protalix BioTherapeutics announced that it has chosen Mr. Shlomo Yanai as chairman of the company\'s board of directors, effective on July 24, 2014. Mr. Zeev Bronfeld, the interim Chairman of the Board, will remain a member of the Board of Directors. Mr. Yanai served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 until 2012. Previously, Mr. Yanai was the President and Chief Executive Officer of Makhteshim Agan Industries (now Adama), a leading global agro-chemicals company. Mr. Yanai also served as a member of the Board of Directors of the Bank Leumi Le-Israel, LycoRed Natural Products Industries and I.T.L. Optronics Ltd.
Financial terms:
Latest news:
Is general: Yes
